HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IFF

This article was originally published in The Rose Sheet

Executive Summary

North American fragrance sales increased 3% in second quarter and 4% after six months, CEO Richard Goldstein told analysts during a July 20 conference call. Sales in Latin America increased 14% for the quarter, and Asia Pacific revenues were up 7%. Overall fragrance sales rose 1%, while consolidated sales slipped 1% $368.8 mil. Goldstein, who took IFF's helm June 1, is developing a strategic plan to drive top line growth while enhancing shareholder value (1"The Rose Sheet" May 1, p. 11). "Customers want [IFF] to be more engaged in product development and provide better awareness of consumer needs and expectations," Goldstein told analysts. The supplier's last restructuring effort in June 1999 involved a 5% cut workforce

Latest Headlines
See All
UsernamePublicRestriction

Register

RS008240

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel